Shares of FMC Corporation surged as much as 11.7% to $11.19 after the struggling crop-chemicals maker announced a $400 million minority equity investment from Belgium-based Tessenderlo Group at $13.30 per share — a roughly 19% premium to yesterday's close of $10.01. The deal hands Tessenderlo an approximate 20% stake and throws a financial rope to a company that just posted disappointing second-quarter results and slashed its full-year outlook. Tessenderlo's $400 Million Bet on FMC Offers a Premium — But Can It Rescue a Company That Has Lost Over 90% of Its Value?
Shares of FMC Corporation jumped 11.7% to $11.19 after the crop-chemicals maker paired weak second-quarter earnings with news of a $400 million minority equity investment from Belgium's Tessenderlo Group at $13.30 per share — a 19% premium to yesterday's battered close of $10.01. The deal, announced alongside a steep earnings miss, is being treated by investors as a survival mechanism for a company drowning in debt.
A Familiar Playbook: Sell a Piece of Yourself to Stay Afloat
The investment ends a strategic review that began in February, which had included exploring a potential sale of the entire company. That no outright buyer emerged speaks volumes. FMC's top priority for 2026 is paying down $1 billion in debt through asset sales and licensing agreements.
The company carries roughly $4.2 billion in total debt , and its debt-to-equity ratio of 2.49 ranks worse than 96.5% of agriculture-industry peers. The $400 million helps, but it covers barely 10% of that debt mountain.
The Numbers Behind Q2 Are Ugly
FMC reported Q2 revenue of $867 million, down 17% year-over-year , while adjusted EBITDA fell 26% to $153 million.
Management lowered its full-year outlook, citing a tougher economic backdrop.
Updated guidance now calls for EPS of $1.19–$1.49 versus a Street consensus of $1.68, and revenue of $3.5–$3.7 billion against expectations of $3.7 billion. The investment premium looks generous until you realize FMC's fundamentals are deteriorating in real time.
The $13.30 Price Tag Sounds Good — In Context, Less So Tessenderlo is paying $13.30, well above today's price — but FMC traded above $120 in early 2022 and its 52-week high is $42.77. The deal price represents a 90% discount to the 2022 peak. It's actually below where the stock traded as recently as June 1. Existing shareholders still face massive dilution from the new shares issued to Tessenderlo.
What Tessenderlo Sees — and What the Market Should Question
Tessenderlo's CEO cited FMC's "new generation of proprietary molecules" as the draw — essentially, next-generation pesticides that could replace revenue lost from the expiration of patent protection on FMC's once-blockbuster insecticide.
Analysts' average rating is "Hold," with a 12-month target of $15.56 — a bet that recovery is possible but far from certain. The cash infusion buys time, not a turnaround. Whether FMC's pipeline can fill a $4 billion debt hole remains the open question.